Clinical experiment designed to assess clinical efficacy targeting HSP90AA1/LRP1/SNAP25 in human. Primary outcome: Validate Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauopathy
Description
Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauopathy
Background and Rationale
4R-tauopathies, including progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), represent devastating neurodegenerative disorders characterized by accumulation of four-repeat tau protein. Despite promising preclinical results, anti-tau immunotherapies have shown variable clinical efficacy, highlighting the urgent need for biomarkers that can predict therapeutic response. Tau PET imaging using second-generation tracers like [18F]PI-2620 provides unprecedented ability to visualize tau distribution patterns in living patients, revealing substantial heterogeneity in tau burden and anatomical distribution across 4R-tauopathy patients. This study addresses a critical knowledge gap by investigating whether baseline tau PET patterns can serve as predictive biomarkers for anti-tau immunotherapy response....
Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauopathy
Background and Rationale
4R-tauopathies, including progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), represent devastating neurodegenerative disorders characterized by accumulation of four-repeat tau protein. Despite promising preclinical results, anti-tau immunotherapies have shown variable clinical efficacy, highlighting the urgent need for biomarkers that can predict therapeutic response. Tau PET imaging using second-generation tracers like [18F]PI-2620 provides unprecedented ability to visualize tau distribution patterns in living patients, revealing substantial heterogeneity in tau burden and anatomical distribution across 4R-tauopathy patients. This study addresses a critical knowledge gap by investigating whether baseline tau PET patterns can serve as predictive biomarkers for anti-tau immunotherapy response. Our central hypothesis posits that patients with predominantly cortical tau burden will demonstrate superior therapeutic responses compared to those with primarily brainstem/subcortical distribution, based on the rationale that cortical tau deposits are more accessible to systemically administered antibodies due to higher blood-brain barrier permeability in cortical regions and reduced physical barriers compared to deep brain structures. This prospective, multicenter clinical trial will employ a precision medicine approach, stratifying 4R-tauopathy patients based on baseline tau PET patterns before initiating anti-tau immunotherapy. The study design integrates advanced neuroimaging, comprehensive clinical assessments, and biomarker analyses to establish tau distribution as a companion diagnostic. Key measurements include quantitative tau PET standardized uptake value ratios (SUVRs) across predefined brain regions, clinical severity scores (PSP Rating Scale, CBD scale), and safety parameters. Secondary analyses will examine correlations between tau burden, neuroinflammation markers, and treatment response trajectories. The innovation lies in applying spatial pattern recognition to tau PET data for therapeutic stratification, potentially revolutionizing treatment selection in 4R-tauopathies. This approach could identify patients most likely to benefit from costly anti-tau therapies while sparing non-responders from unnecessary exposure and adverse effects. The significance extends beyond 4R-tauopathies, establishing a paradigm for using molecular imaging patterns as predictive biomarkers across neurodegenerative diseases, ultimately advancing personalized medicine in neurodegeneration treatment.
This experiment directly tests predictions arising from the following hypotheses:
TREM2-mediated microglial tau clearance enhancement
LRP1-Dependent Tau Uptake Disruption
TREM2 Conformational Stabilizers for Synaptic Discrimination
HSP90-Tau Disaggregation Complex Enhancement
Synaptic Vesicle Tau Capture Inhibition
Experimental Protocol
Phase 1 (Months 1-6): Recruit 120 patients with clinically diagnosed 4R-tauopathy (PSP=80, CBD=40) from 6 academic medical centers. Inclusion criteria: age 45-80, disease duration 1-5 years, PSP Rating Scale 20-60. Exclusion criteria: significant cardiovascular disease, prior anti-tau therapy. Conduct baseline assessments including tau PET imaging with [18F]PI-2620 (150-300 MBq injection, 90-110 min post-injection acquisition), structural MRI, clinical rating scales, neuropsychological testing, and CSF collection for p-tau217, NfL, and inflammatory markers. Phase 2 (Months 7-12): Analyze tau PET images using FreeSurfer ROI-based analysis and voxel-wise statistical parametric mapping. Calculate cortical composite SUVR (frontal, parietal, temporal regions) and subcortical composite SUVR (brainstem, basal ganglia). Stratify patients into High-Cortical (cortical SUVR >1.5, cortical:subcortical ratio >1.2) versus Low-Cortical groups. Randomize within strata to receive either anti-tau monoclonal antibody (15 mg/kg IV monthly) or placebo (2:1 ratio). Phase 3 (Months 13-24): Administer study drug with monthly safety assessments including ARIA monitoring via MRI every 3 months. Conduct efficacy evaluations at months 6, 12, and 18 post-treatment initiation. Repeat tau PET at 12 months to assess treatment-related changes. Primary endpoint: change in PSP Rating Scale from baseline to 18 months. Secondary endpoints include tau PET SUVR changes, CSF biomarker levels, and safety parameters. Phase 4 (Months 25-30): Complete statistical analyses using mixed-effects models with treatment-by-strata interactions, safety database lock, and regulatory submission preparation.
Expected Outcomes
High-cortical tau patients receiving anti-tau therapy will demonstrate 35% greater improvement in PSP Rating Scale compared to low-cortical patients (Cohen's d=0.65, p<0.01)
Cortical tau SUVR will decrease by 15-25% in high-cortical responders versus <5% in low-cortical patients on active treatment (p<0.005)
CSF p-tau217 levels will show 40% greater reduction in high-cortical patients compared to low-cortical patients receiving active treatment (effect size=0.8)
Treatment-emergent adverse events will be similar across stratification groups (difference <10%), confirming safety profile independence from tau distribution patterns
Cortical:subcortical tau ratio >1.2 will predict treatment response with 78% positive predictive value and 72% negative predictive value
Neuroinflammation markers (CSF YKL-40, sTREM2) will show greater reduction in high-cortical responders, correlating with tau burden changes (r=0.6-0.8, p<0.01)
Success Criteria
• Significant treatment-by-strata interaction (p<0.05) demonstrating differential response based on baseline tau PET patterns
• High-cortical patients show ≥30% greater clinical improvement compared to low-cortical patients on active treatment
• Positive predictive value for treatment response using cortical tau burden cutoff achieves ≥75% accuracy
• Safety profile remains acceptable with serious adverse event rate <15% and no increased risk in high-cortical patients
• Correlation between tau PET changes and clinical outcomes reaches statistical significance (r≥0.4, p<0.05)
• At least 80% of enrolled patients complete the 18-month treatment period with evaluable efficacy data
TARGET GENE
HSP90AA1/LRP1/SNAP25
MODEL SYSTEM
human
ESTIMATED COST
$7,500,000
TIMELINE
55 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Validate Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauopathy
Phase 1 (Months 1-6): Recruit 120 patients with clinically diagnosed 4R-tauopathy (PSP=80, CBD=40) from 6 academic medical centers. Inclusion criteria: age 45-80, disease duration 1-5 years, PSP Rating Scale 20-60. Exclusion criteria: significant cardiovascular disease, prior anti-tau therapy. Conduct baseline assessments including tau PET imaging with [18F]PI-2620 (150-300 MBq injection, 90-110 min post-injection acquisition), structural MRI, clinical rating scales, neuropsychological testing, and CSF collection for p-tau217, NfL, and inflammatory markers. Phase 2 (Months 7-12): Analyze tau PET images using FreeSurfer ROI-based analysis and voxel-wise statistical parametric mapping.
...
Phase 1 (Months 1-6): Recruit 120 patients with clinically diagnosed 4R-tauopathy (PSP=80, CBD=40) from 6 academic medical centers. Inclusion criteria: age 45-80, disease duration 1-5 years, PSP Rating Scale 20-60. Exclusion criteria: significant cardiovascular disease, prior anti-tau therapy. Conduct baseline assessments including tau PET imaging with [18F]PI-2620 (150-300 MBq injection, 90-110 min post-injection acquisition), structural MRI, clinical rating scales, neuropsychological testing, and CSF collection for p-tau217, NfL, and inflammatory markers. Phase 2 (Months 7-12): Analyze tau PET images using FreeSurfer ROI-based analysis and voxel-wise statistical parametric mapping. Calculate cortical composite SUVR (frontal, parietal, temporal regions) and subcortical composite SUVR (brainstem, basal ganglia). Stratify patients into High-Cortical (cortical SUVR >1.5, cortical:subcortical ratio >1.2) versus Low-Cortical groups. Randomize within strata to receive either anti-tau monoclonal antibody (15 mg/kg IV monthly) or placebo (2:1 ratio). Phase 3 (Months 13-24): Administer study drug with monthly safety assessments including ARIA monitoring via MRI every 3 months. Conduct efficacy evaluations at months 6, 12, and 18 post-treatment initiation. Repeat tau PET at 12 months to assess treatment-related changes. Primary endpoint: change in PSP Rating Scale from baseline to 18 months. Secondary endpoints include tau PET SUVR changes, CSF biomarker levels, and safety parameters. Phase 4 (Months 25-30): Complete statistical analyses using mixed-effects models with treatment-by-strata interactions, safety database lock, and regulatory submission preparation.
Expected Outcomes
High-cortical tau patients receiving anti-tau therapy will demonstrate 35% greater improvement in PSP Rating Scale compared to low-cortical patients (Cohen's d=0.65, p<0.01)
Cortical tau SUVR will decrease by 15-25% in high-cortical responders versus <5% in low-cortical patients on active treatment (p<0.005)
CSF p-tau217 levels will show 40% greater reduction in high-cortical patients compared to low-cortical patients receiving active treatment (effect size=0.8)
Treatment-emergent adverse events will be similar across stratification groups (difference <10%), confirming safety profile in
...
High-cortical tau patients receiving anti-tau therapy will demonstrate 35% greater improvement in PSP Rating Scale compared to low-cortical patients (Cohen's d=0.65, p<0.01)
Cortical tau SUVR will decrease by 15-25% in high-cortical responders versus <5% in low-cortical patients on active treatment (p<0.005)
CSF p-tau217 levels will show 40% greater reduction in high-cortical patients compared to low-cortical patients receiving active treatment (effect size=0.8)
Treatment-emergent adverse events will be similar across stratification groups (difference <10%), confirming safety profile independence from tau distribution patterns
Cortical:subcortical tau ratio >1.2 will predict treatment response with 78% positive predictive value and 72% negative predictive value
Neuroinflammation markers (CSF YKL-40, sTREM2) will show greater reduction in high-cortical responders, correlating with tau burden changes (r=0.6-0.8, p<0.01)
Success Criteria
• Significant treatment-by-strata interaction (p<0.05) demonstrating differential response based on baseline tau PET patterns
• High-cortical patients show ≥30% greater clinical improvement compared to low-cortical patients on active treatment
• Positive predictive value for treatment response using cortical tau burden cutoff achieves ≥75% accuracy
• Safety profile remains acceptable with serious adverse event rate <15% and no increased risk in high-cortical patients
• Correlation between tau PET changes and clinical outcomes reaches statistical significance (r≥0.4, p<0.05)
• At lea
...
• Significant treatment-by-strata interaction (p<0.05) demonstrating differential response based on baseline tau PET patterns
• High-cortical patients show ≥30% greater clinical improvement compared to low-cortical patients on active treatment
• Positive predictive value for treatment response using cortical tau burden cutoff achieves ≥75% accuracy
• Safety profile remains acceptable with serious adverse event rate <15% and no increased risk in high-cortical patients
• Correlation between tau PET changes and clinical outcomes reaches statistical significance (r≥0.4, p<0.05)
• At least 80% of enrolled patients complete the 18-month treatment period with evaluable efficacy data